Management of mantle cell lymphoma

Meusers, P.; Hense, Jörg

doi:10.1007/s002770050545

Cited by 17 publications

(10 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…15 Other common clinical features of MCL include infiltration of the bone marrow (60-87% of cases), spleen (33-75%), blood (20-58%) or liver (35%), multiple gastrointestinal involvement (15-40%) and B symptoms (25-50%). 13,15 Infiltration of the central nervous system has also been reported (4% in one study). 16 The prognosis of MCL patients is generally poor, with a median survival of 36 months.…”

Section: Mantle Cell Lymphomamentioning

confidence: 87%

“…In a minority of patients, specifically those at low risk (stage I/II), radiotherapy has proved to be effective. 13. However, relapses are frequent and the median time to treatment failure can be as short as 14 months.…”

Section: Mantle Cell Lymphomamentioning

confidence: 96%

“…Immunophenotypically, these lymphocytes express a distinctive pattern of cell-surface markers, notably CD19, CD20, CD22, surface immunoglobulin IgM and IgD, and commonly CD5; expression of CD10 and CD23 are usually absent. 12,13 In the majority of MCL cases, the hallmark cytogenetic feature is the translocation t(11;14)(q13:q32), which is thought to underlie the pathogenesis of this disorder.…”

Section: Mantle Cell Lymphomamentioning

confidence: 99%

“…Other adverse prognostic factors include age 465 years, advanced stage, high lactic dehydrogenase levels, bone marrow involvement, poor performance status and B symptoms. 13,15,17 A full account of the prognostic factors, clinical features, diagnosis and genetics of MCL is reviewed elsewhere. 12,15,18,19 Treatment options Patients with MCL typically have only a moderate outcome in terms of survival with conventional chemotherapies despite the fact that treatment achieves a relatively high first-line remission rate (up to 90%).…”

Section: Mantle Cell Lymphomamentioning

confidence: 99%

See 3 more Smart Citations

Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies

Johnson¹

2004

Hematol J

View full text Add to dashboard Cite

After initial efforts using fludarabine as a single agent in the treatment of acute leukemia, its activity at lower and safer doses was demonstrated in chronic lymphocytic leukemia (CLL) patients who were refractory or had relapsed from traditional chemotherapies, representing a highly effective therapy for this condition. Fludarabine was also rapidly shown to be beneficial as first-line therapy in CLL. There is now considerable evidence that fludarabine is an effective agent in non-Hodgkin's lymphoma and in combination therapy for acute myeloid leukemia. Further, good responses are achieved when fludarabine-based approaches are used as conditioning regimens prior to transplantation procedures. The actions of fludarabine are not restricted to these settings and its potential role in the treatment of a range of uncommon T- and B-cell lymphoid malignancies is slowly emerging. This review will focus on the characteristics and treatment options for two B-cell disorders, mantle cell lymphoma and Waldenström's macroglobulinemia, with emphasis on the clinical activity of fludarabine. Additionally, the advantages of using fludarabine-containing regimens for a range of other lymphoproliferative conditions will also be discussed. These include B-cell neoplasms such as the CLL variant prolymphocytic leukemia, hairy cell leukemia and mucosa-associated lymphoid tissue-derived lymphomas; the T-cell disorders cutaneous T-cell lymphoma, angioimmunoblastic lymphadenopathy and other rarer T-cell diseases; and aggressive variants of non-Hodgkin's lymphoma including Richter's syndrome.

show abstract

Section: Mantle Cell Lymphomamentioning

confidence: 87%

Section: Mantle Cell Lymphomamentioning

confidence: 96%

Section: Mantle Cell Lymphomamentioning

confidence: 99%

Section: Mantle Cell Lymphomamentioning

confidence: 99%

See 2 more Smart Citations

Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies

Johnson¹

2004

Hematol J

View full text Add to dashboard Cite

show abstract

“…A mediana de sobrevida dos pacientes portadores do linfoma das células do manto é de três a quatro anos, sendo conhecido como um dos subtipos de pior prognóstico dentre os linfomas não-Hodgkin (ARGATOFF et al, 1997;NORTON et al, 1995;PITTALUGA et al, 1996;ZUCCA et al, 1995). A resposta a qualquer regime de quimioterapia geralmente é de curta duração, e até recentemente era considerado incurável mesmo com a utilização de regimes agressivos de tratamento (MEUSERS;HENSE, 1999). Nos últimos anos, porém, foram alcançados resultados promissores com protocolos de quimioterapia em altas dosagens, em associação ao transplante de células-tronco hematopoéticas (KHOURI et al, 1998).…”

Section: Características Clínicas E Imunofenotípicasunclassified